Min Guang Wang, MD in Longview, WA - Pathology

Min Guang Wang, MD is a Pathology - Anatomic Pathology & Clinical Pathology physician based in Longview, Washington. Min Guang Wang is licensed to practice in Washington (license number MD00046965) and his current practice location is 1217 14th Avenue, Longview, Washington. He can be reached at his office (for appointments etc.) via phone at (360) 425-5620.

NPI number for Min Guang Wang is 1194833426 and his current mailing address is Po Box 3012, Longview, Washington. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1194833426.

Contact Information

	Min Guang Wang, MD
	1217 14th Avenue, Longview, WA 98632
	(360) 425-5620
	(360) 425-7219

Physician's Profile

Full Name	Min Guang Wang
Gender	Male
Speciality	Pathology - Anatomic Pathology & Clinical Pathology
Location	1217 14th Avenue, Longview, Washington
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1194833426
Provider Enumeration Date: 08/28/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Min Guang Wang such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1194833426	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207ZP0102X	Pathology - Anatomic Pathology & Clinical Pathology	MD00046965 (Washington)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Min Guang Wang is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Min Guang Wang, MD Po Box 3012, Longview, WA 98632 Ph: (360) 425-5620	Min Guang Wang, MD 1217 14th Avenue, Longview, WA 98632 Ph: (360) 425-5620

News Archive

Appeals court upholds five-year exclusivity period for Shire's VYVANSE

Shire plc, the global specialty biopharmaceutical company, announces that the U.S. Court of Appeals for the District of Columbia Circuit has affirmed the ruling of the U.S. District Court for the District of Columbia and the U.S. Food and Drug Administration to grant five-year New Chemical Entity exclusivity to lisdexamfetamine dimesylate, currently marketed by Shire U.S. Inc. under the name VYVANSE(R).

Delivering genetic test results over the phone may help ease cost, burden for at-risk cancer patients

Delivering genetic test results to patients at risk for cancer-causing genetic mutations over the phone helps to ease cost and transportation burdens and, compared to receiving results in person, does not cause patients additional stress, according to a new study from the Abramson Cancer Center of the University of Pennsylvania which will be presented at the American Society of Clinical Oncology Annual Meeting.

Survey to help assess pediatric emergency readiness of hospital EDs

Marianne Gausche-Hill, M.D., and Kate Remick, M.D. - lead investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) - are spearheading a statewide, web-based survey scheduled to roll out Jan. 6, 2012 that will help assess the pediatric emergency readiness of hospital emergency departments.

Nurses stop bed closures as government makes offer

Nurses who were closing down beds over staffing issues have stopped but have not ruled out the possibility of more bed closures in the future. Beds at the Tamworth Base Hospital that were closed before Christmas re-opened yesterday (Thursday). A total 570 beds were reopened. The New South Wales Nurses Association is considering an offer by the State Government. The protest was in favour of a standard minimum ratio of one nurse for every four patients.

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

Pathology Doctors in Longview, WA

Robert E Sandstrom, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1217 14th Ave, Longview, WA 98632 Phone: 360-425-5620 Fax: 360-425-7219
Laila A Naqib-osman, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 720 14th Ave, Longview, WA 98632 Phone: 360-501-8315 Fax: 360-425-7219
Morrill T Moorehead, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1217 14th Ave, Longview, WA 98632 Phone: 360-425-5620 Fax: 360-425-7219

Min Guang Wang, MD - Pathology in Longview, WA